A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
about
Diagnosis and treatment of diarrhea-predominant irritable bowel syndromeIBS and the role of otilonium bromide.Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-DIrritable bowel syndrome: current and emerging treatment options.A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.New therapeutic option for irritable bowel syndrome: serum-derived bovine immunoglobulinEvidence-based clinical practice guidelines for irritable bowel syndrome.Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.Efficacy of ramosetron in male patients with irritable bowel syndrome with diarrhea (neurogastroenterol motil 2011;23:1098-1104).Targeted therapies for diarrhea-predominant irritable bowel syndrome.Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trialsRecent developments in the therapy of irritable bowel syndrome.New treatments for irritable bowel syndrome in womenA 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.The trials and tribulations of drug development for functional gastrointestinal disorders.Medical management of irritable bowel syndrome in 2008: current and future directions.Updates on treatment of irritable bowel syndrome.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Update on irritable bowel syndrome and gender differences.Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis.Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome.American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.Adverse events appear to unblind clinical trials in irritable bowel syndrome.Post-Infectious Irritable Bowel Syndrome.Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint.Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis.Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
P2860
Q26765272-79D5C948-3E53-47CD-8AC0-8BF38A4F5C0BQ33456428-E17246A9-BFA4-435B-AE65-DEBC94C0BB5BQ33466527-555B2068-BBE3-4193-9381-CD682B65AFBDQ33667183-37829B67-8409-4EA2-8534-EB064026DC56Q34010550-5D555178-7DC3-45BE-BE22-7EBABA771EC4Q34237231-DBBA62B3-F7AC-43A7-A018-4244AF5E4694Q34409173-7A417711-F183-4A05-9441-3DC9A84ABFEEQ35052602-DB458539-B106-4D4A-B38A-97D6B8B7CAF3Q35188643-40C6249C-DD5D-432F-9537-95787066C08AQ35513973-C685B7DB-2CE8-47D5-B5CE-99C6B5460547Q35586987-2546D844-D40A-4F8B-BDF6-B43BFE744C40Q35885931-6F398459-65B1-4FB9-89A0-E0688F5B724AQ36065945-616A96CE-C684-425B-BCE8-EC3BA5489B30Q36297736-4667B55B-58A4-4F2F-A67A-4E442A1BC990Q36307366-30CEE842-0132-403E-857E-701CCD52840BQ37071175-0DAE188A-46BB-43D1-B160-D4C300483241Q37120300-9A1ECE59-0694-441B-A2CA-669BF4C99A20Q37130608-4305331B-E947-4549-8657-0C3E97C9128FQ37134572-7034789E-40C5-4334-8FC3-B011C72FBAB0Q37141316-E3A76662-F049-44F1-9EC2-B5FC69B1D83CQ37156627-95404F22-09F5-481A-BCCB-C1523B85F7E9Q37164063-8DA1CBEA-3B38-4DD2-B2A2-A3F498054109Q37205403-F6E29686-95AE-406F-B7FC-86E65595BB0AQ37346021-E5AEC3F0-6060-4013-AC65-1F6F693D710EQ37496549-3680152D-63B6-428F-99D1-5351ED3F89E9Q37505588-AFF45C57-442A-41DF-AD11-43281F9AAD3BQ37632259-B1B368BB-16CA-4E07-840D-8C04C3BF4E57Q38011936-383DC64E-6CB7-4A50-A3B9-284C4C760017Q38194631-827DDF78-8E59-4C35-9244-A87A6B1A7CCFQ38236812-2D58A950-65B3-45F6-8284-F7281714398CQ38630721-E43A8910-25D0-4D95-8D88-DF2CD67F55B0Q39267149-30C3A6BF-2082-4784-9364-3539DC8E9F76Q41078536-A8FDF92B-F673-47C5-90AE-65E71DE2B88BQ43144574-30896A4E-0EB9-41BC-A97A-A44BFE595C15Q43171523-887A4148-DD65-47AA-B3CB-E797A5D6D5F3Q43439726-5B363404-FE0D-4C16-BE3C-9F29C0C304DBQ52086430-5D03B389-1508-4101-A0DE-C9F85E4E75A2Q55030643-A4AF0724-0F3C-4A39-A349-E7AD393AE136Q55448021-EC156035-85D5-4DA0-96A4-EA341209A097Q57070200-2BDD3824-08AA-4B6C-A7AB-3046EBB41FBC
P2860
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
A randomized, double-blind, pl ...... vere diarrhea-predominant IBS.
@en
A randomized, double-blind, pl ...... vere diarrhea-predominant IBS.
@nl
type
label
A randomized, double-blind, pl ...... vere diarrhea-predominant IBS.
@en
A randomized, double-blind, pl ...... vere diarrhea-predominant IBS.
@nl
prefLabel
A randomized, double-blind, pl ...... vere diarrhea-predominant IBS.
@en
A randomized, double-blind, pl ...... vere diarrhea-predominant IBS.
@nl
P2093
P2860
P1476
A randomized, double-blind, pl ...... vere diarrhea-predominant IBS.
@en
P2093
Amy T Heath
Eric G Carter
Marquita West
Richard Krause
Susan H Gordon
Teresa Perschy
Vanessa Ameen
P2860
P304
P356
10.1111/J.1572-0241.2007.01282.X
P407
P577
2007-05-17T00:00:00Z